Publications by authors named "Haile Tecle"

Claim this Profile
T
Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.
Jeff B Smaill, Andrea J Gonzales, Julie A Spicer, Helen Lee, Jessica E Reed, Haile Tecle

J Med Chem· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced selectivity profile of pyrazole-urea based DFG-out p38alpha inhibitors.
Hu Liu, Cyrille Kuhn, Frederic Feru, Suzanne L Jacques, Gayatri D Deshmukh, Haile Tecle

Bioorg Med Chem Lett· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The design, synthesis and potential utility of fluorescence probes that target DFG-out conformation of p38alpha for high throughput screening binding assay.
Haile Tecle, Frederic Feru, Hu Liu, Cyrille Kuhn, Glen Rennie

Chem Biol Drug Des· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond the MEK-pocket: can current MEK kinase inhibitors be utilized to synthesize novel type III NCKIs? Does the MEK-pocket exist in kinases other than MEK?
Haile Tecle, Jianxing Shao, Yanhong Li, Michael Kothe, Steven Kazmirski

Bioorg Med Chem Lett· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles-O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase).
Joseph S Warmus, Cathlin Flamme, Lu Yan Zhang, Stephen Barrett, Alexander Bridges, Haile Tecle

Bioorg Med Chem Lett· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.
Stephen D Barrett, Alexander J Bridges, David T Dudley, Alan R Saltiel, James H Fergus, Haile Tecle

Bioorg Med Chem Lett· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor.
Andrea J Gonzales, Kenneth E Hook, Irene W Althaus, Paul A Ellis, Erin Trachet, Haile Tecle

Mol Cancer Ther· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase.
Julie A Spicer, Gordon W Rewcastle, Michael D Kaufman, Shannon L Black, Mark S Plummer, Haile Tecle

J Med Chem· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms.
Melissa J Thiel, Caralee J Schaefer, Mark E Lesch, James L Mobley, David T Dudley, Haile Tecle

Arthritis Rheum· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-(6,7-dichloro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-N-alkylsulfonamides as peripherally restricted N-methyl-D-aspartate receptor antagonists for the treatment of pain.
Christopher Deur, Arun K Agrawal, Heidi Baum, John Booth, Susan Bove, Haile Tecle

Bioorg Med Chem Lett· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.
Jeffrey F Ohren, Huifen Chen, Alexander Pavlovsky, Christopher Whitehead, Erli Zhang, Haile Tecle

Nat Struct Mol Biol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis